Tags

Type your tag names separated by a space and hit enter

Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
J Intern Med. 2008 Oct; 264(4):315-32.JI

Abstract

Bisphosphonates are the current mainstay of treatment for postmenopausal osteoporosis. Although daily oral dosing is effective, it is associated with poor compliance, partly because of the pre and postdose fasting and posture requirements. This negatively impacts treatment outcomes, leading to a reduced clinical benefit. Improved, yet still suboptimal adherence has been noticed with less frequent bisphosphonate dosing e.g. once-weekly and once-monthly oral regimens. The recently approved quarterly intravenous (i.v.) injection regimen of ibandronate and yearly i.v. infusion of zoledronic acid are attractive options in the management of postmenopausal osteoporosis. These regimens may assure quarterly and year long compliance.

Authors+Show Affiliations

Leuven University, Department of Experimental Medicine, Leuven, Belgium. steven.boonen@uz.kuleuven.ac.beNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

18823505

Citation

Boonen, S, et al. "Recent Developments in the Management of Postmenopausal Osteoporosis With Bisphosphonates: Enhanced Efficacy By Enhanced Compliance." Journal of Internal Medicine, vol. 264, no. 4, 2008, pp. 315-32.
Boonen S, Vanderschueren D, Venken K, et al. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Intern Med. 2008;264(4):315-32.
Boonen, S., Vanderschueren, D., Venken, K., Milisen, K., Delforge, M., & Haentjens, P. (2008). Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. Journal of Internal Medicine, 264(4), 315-32. https://doi.org/10.1111/j.1365-2796.2008.02010.x
Boonen S, et al. Recent Developments in the Management of Postmenopausal Osteoporosis With Bisphosphonates: Enhanced Efficacy By Enhanced Compliance. J Intern Med. 2008;264(4):315-32. PubMed PMID: 18823505.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. AU - Boonen,S, AU - Vanderschueren,D, AU - Venken,K, AU - Milisen,K, AU - Delforge,M, AU - Haentjens,P, PY - 2008/10/1/pubmed PY - 2008/10/22/medline PY - 2008/10/1/entrez SP - 315 EP - 32 JF - Journal of internal medicine JO - J Intern Med VL - 264 IS - 4 N2 - Bisphosphonates are the current mainstay of treatment for postmenopausal osteoporosis. Although daily oral dosing is effective, it is associated with poor compliance, partly because of the pre and postdose fasting and posture requirements. This negatively impacts treatment outcomes, leading to a reduced clinical benefit. Improved, yet still suboptimal adherence has been noticed with less frequent bisphosphonate dosing e.g. once-weekly and once-monthly oral regimens. The recently approved quarterly intravenous (i.v.) injection regimen of ibandronate and yearly i.v. infusion of zoledronic acid are attractive options in the management of postmenopausal osteoporosis. These regimens may assure quarterly and year long compliance. SN - 1365-2796 UR - https://www.unboundmedicine.com/medline/citation/18823505/Recent_developments_in_the_management_of_postmenopausal_osteoporosis_with_bisphosphonates:_enhanced_efficacy_by_enhanced_compliance_ L2 - https://doi.org/10.1111/j.1365-2796.2008.02010.x DB - PRIME DP - Unbound Medicine ER -